Pieter Muntendam, MD

Pieter Muntendam, MDPieter Muntendam is a physician by training who devoted his career to medical innovation by developing novel pharmaceuticals, medical devices, and services for payors and employers to reduce the burden of common conditions. Dr Muntendam had a successful executive career with leading international companies such as Johnson & Johnson, GlaxoSmithKline (GSK), and Organon (now Merck) before he embarked on an entrepreneurial career that included starting and leading pharmaceutical, device and medical services companies. Dr Muntendam has raised over $250M in public and private funding as CEO of early-stage companies and led the initial public offering of BG Medicine. He has led the development of a potentially transformative diagnostic from inception to FDA clearance and commercial introduction and successfully negotiated and implemented numerous partnership deals with leading manufacturers, the public sector and a national payer.

Volker Lauterbach

Volker LauterbachVolker Lauterbach is a healthcare consultant and Pharmaceutical industry veteran. Before founding his consulting company Vate Consultants Inc. he spent 20+ years with Bayer Healthcare. His postings led him to work in Asia, Europe and North America., working in global roles as well as in country executive roles. His expertise lies in commercial and strategic work in therapeutic areas spanning General Medicine as well as Specialty therapeutics.

John Kaiser

John Kaiser, Chief Business OfficerJohn Kaiser currently serves as Chief Business Officer and is a member of the Executive Management Team of Cerecor Inc., where he previously held positions as Chief Commercial Officer and Vice President, Commercialization and Business Development. Mr. Kaiser is also the co-founder & CEO of Denysias Bioscience in San Diego, where he led funding and licensing efforts. Prior to Denysias, he served as Vice President of Commercial & Business Development at ACADIA Pharmaceuticals in San Diego with responsibilities for strategic marketing and licensing efforts. Prior to ACADIA, Mr. Kaiser held numerous positions of increasing responsibilities at Eli Lilly & Company that spanned more than 25 years. At Lilly, Mr. Kaiser held various assignments in sales, marketing and general management in the US and Europe (including the UK and the Netherlands).